-
FDA Advisory Panel Recommends Expanding Access to Six Peptides Through Compounding
An FDA advisory panel has voted to support the inclusion of six peptides on the agency’s approved list for pharmacy compounding, potentially expanding patient access to these therapies. The recommendation marks a meaningful step toward broader availability under proper regulatory oversight.
-
New Phase III Trial Explores Combining Cetuximab with Pembrolizumab for Recurrent Head and Neck Cancer
A new phase III clinical trial is investigating whether adding the monoclonal antibody cetuximab to standard pembrolizumab treatment can improve outcomes for patients with recurrent or metastatic head and neck squamous cell carcinoma.
-
New Clinical Trial Explores Amivantamab Combinations for Early-Stage EGFR-Mutated Lung Cancer
A newly launched study is investigating whether pairing amivantamab with lazertinib or standard chemotherapy can help shrink resectable EGFR-mutated non-small cell lung cancer before surgery. The trial reflects ongoing efforts to improve treatment options for patients with this common lung cancer subtype.
-
New Phase III Trial Explores Adding Targeted Immunotherapy to Hodgkin Lymphoma Treatment
A phase III clinical trial is now comparing standard chemotherapy for early-stage Hodgkin lymphoma to a regimen that adds two targeted therapies, brentuximab vedotin and nivolumab, in hopes of improving survival and reducing side effects.
-
New Trial Aims to Sharpen MRSA Treatment by Comparing Two Leading Therapies
A new randomized trial will directly compare daptomycin, a cyclic lipopeptide antibiotic, against vancomycin for treating MRSA bloodstream infections, aiming to guide better treatment choices.
-
Lilly’s Triple-Agonist Retatrutide Shows Powerful Weight Loss in Pivotal Phase 3 Trial
Eli Lilly’s investigational triple agonist retatrutide produced substantial weight loss in a pivotal Phase 3 obesity trial, marking another milestone for next-generation metabolic peptides.
-
FDA Advisory Panel Votes to Ease Restrictions on Four Peptides
An FDA advisory panel has voted in favor of loosening restrictions on four peptide compounds, a move that could expand access and support further research and development.
-
FDA Advisory Panel Backs Expanded Access to Certain Peptide Therapies
An FDA advisory panel has voiced support for broadening the availability of select peptide-based treatments, a signal that could pave the way for wider patient access. The recommendation reflects growing regulatory confidence in peptide therapeutics.
-
FDA Advisory Panel Signals Support for Compounded Peptide Access
An FDA advisory panel has reportedly recommended allowing continued compounding of certain unapproved peptides, a move that could preserve patient access to these therapies while formal approval pathways progress.
-
Retatrutide Shows Remarkable Weight-Loss Results, Rivaling Surgical Outcomes
Early clinical data on retatrutide, a new investigational peptide, show participants losing up to 30% of body weight—results comparable to bariatric surgery. Experts see this as a major step forward in non-surgical obesity treatment.